EPISODE · Sep 25, 2023 · 1H 31M
Freely Filtered 062: Inaxaplin for APOL1 Kidney Disease
from Freely Filtered, a NephJC Podcast · host joel topf
The Filtrate:Joel TopfJennie LinJosh WaitzmanWith Special Guest:AC Gomez MedPeds nephrology fellow at Mass General/Brigham and Boston Children’s | TwitterGentian Hall Assistant Professor of Medicine Duke Department of MedicineEditor:Sophia AmbrusoShow Notes:APOL1 review by the OG Scientists APOL1 Nephropathy: From Genetics to Clinical ApplicationsMYH9 and APOL1 connection: The population genetics of chronic kidney disease: insights from the MYH9–APOL1 locusMartin Pollack LabVertex LabWorldwide Frequencies of APOL1 Renal Risk Variants (NEJM)Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-FunctionEnd-Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1Apolipoprotein L1 Risk Variants Associate with Systemic Lupus Erythematosus-Associated Collapsing GlomerulopathyHEK293 Cells WikipediaTubular SecretionsJosh: From Serial and the New York Times: The RetrievalsJennie: Marathon induced hyponatremia (NEJM) Donate to the NKF of Illinoise in honor of Jennie’s really long run Donate to New England Donor Services in honor of Josh’s much shorter ruinGentian: Vivien Thomas wikipedia. HBO Movie: Something the Lord MadeAC: Talking to the FDA about SGLT2i TweetJoel: NephJC 2023 Fund drive
Embed this episode
What this episode covers
Inaxaplin is a small molecule that is in trials for APOL1 associated kidney disease. Genome guided medicine comes to nephrology.
NOW PLAYING
Freely Filtered 062: Inaxaplin for APOL1 Kidney Disease
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.